Question 1

What is the Zenith Drugs Limited IPO?

Accepted Answer

The Zenith Drugs Limited IPO is an SME (Small and Medium Enterprise) Initial Public Offering where Zenith Drugs Limited is offering its shares to the public for the first time. The issue size is ₹51 lakhs with a price band of ₹75-79. This allows retail and institutional investors to become shareholders in the company.

Question 2

When will Zenith Drugs Limited IPO open?

Accepted Answer

The Zenith Drugs Limited IPO was open from 19 February 2024 to 22 February 2024. The subscription period has now ended.

Question 3

What is the lot size of Zenith Drugs Limited IPO?

Accepted Answer

The lot size for Zenith Drugs Limited IPO is 1600 shares, which means the minimum investment required is approximately ₹1,26,400 (1600 shares × ₹75-79). Retail investors can apply for one or more lots, but applying for a single lot typically gives better allotment chances during oversubscription.

Question 4

How to apply for Zenith Drugs Limited IPO?

Accepted Answer

You can apply for the Zenith Drugs Limited IPO through multiple channels: 1) Online broker platforms like Zerodha, Groww, Angel One, Upstox (most convenient); 2) Internet banking using ASBA facility; 3) Through your bank branch. You'll need a Demat account, linked bank account, PAN card, and sufficient funds. The application process involves selecting the IPO, choosing number of lots, selecting bid price (or cutoff), and authorizing the payment via UPI mandate.

Question 5

When is Zenith Drugs Limited IPO allotment?

Accepted Answer

The Zenith Drugs Limited IPO allotment was completed on Expected 5-7 days after closing. You can check your allotment status on the registrar's website (Link Intime, KFintech, or Bigshare) using your PAN number, application number, or Demat details. Allotted shares will be credited to your Demat account before the listing date. If you don't get allotment, your blocked amount will be unblocked automatically.

Question 6

When is Zenith Drugs Limited IPO listing date?

Accepted Answer

The Zenith Drugs Limited IPO was listed on 27 February 2024. On listing day, shares will start trading on the stock exchanges, and you can sell your allotted shares or hold them for long-term investment based on your strategy. Listing price depends on market demand and may be above, below, or at the issue price.

Question 7

Was GMP of Zenith Drugs Limited IPO reliable?

Accepted Answer

The Grey Market Premium (GMP) for Zenith Drugs Limited IPO was ₹35 before listing. The actual listing price was ₹110, giving a listing gain of 39.2% (₹31 per share). The GMP was fairly accurate and close to the actual listing performance. This demonstrates that while GMP can be an indicator, it's not always accurate and should be used alongside fundamental analysis.

Question 8

How much profit have I made if I held Zenith Drugs Limited IPO after allotment?

Accepted Answer

If you were allotted shares at the issue price of ₹79 and held them until now, your current gain is -44.4% (₹-35 per share). For one lot of 1600 shares, your loss would be ₹56,000. On listing day, the stock opened at ₹110 (39.2% gain). The stock has corrected from listing day highs. Remember, past performance doesn't guarantee future results, and investment decisions should be based on the company's fundamentals and your investment goals.

Application	Lots	Shares	Amount
Individual(min) Individual Investors for SME IPO - Investment up to ₹2 lakhs (min 2 lots)	2	3,200	₹2.53L
Individual(max) Individual Investors for SME IPO - Investment up to ₹2 lakhs (min 2 lots)	2	3,200	₹2.53L
SHNI(min) Small HNI - Investment between ₹2 lakhs and ₹10 lakhs	3	4,800	₹3.79L
SHNI(max) Small HNI - Investment between ₹2 lakhs and ₹10 lakhs	7	11,200	₹8.85L
BHNI(min) Big HNI - Investment above ₹10 lakhs	8	12,800	₹10.11L

IPO Master

Zenith Drugs Limited

Market Performance

Stock Price Chart

Market Lot Size

IPO Timeline

IPO Opens

IPO Closes

Allotment

Listing

AI Research Analysis Not Available

Allotment Status

Frequently Asked Questions about Zenith Drugs Limited IPO